Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (191-200 of 238) with videos related to

Pageof 24
Sort By:
Antimicrobial Agents and Chemotherapy|November 26, 2014
First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activityShirin Bruderer, Noémie Hurst, Ruben de Kanter, et al.
Journal of Clinical Pharmacology|February 29, 2008
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsRebecca E Wrishko, Jasper Dingemanse, Albert Yu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 22, 2009
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentanOliver Kummer, Manuel Haschke, Felix Hammann, et al.
Drug Design, Development and Therapy|January 2, 2015
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonistMatthias Hoch, Borje Darpo, Tatiana Remenova, et al.
Clinical Pharmacology and Therapeutics|April 15, 2022
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive SimulatorClemens Muehlan, Sander Brooks, Cedric Vaillant, et al.
Journal of Psychopharmacology (Oxford, England)|June 15, 2012
Orexin receptor antagonism: an ascending multiple-dose study with almorexantPetra Hoever, Sanne L de Haas, Georg Dorffner, et al.
Thrombosis and Haemostasis|January 7, 2021
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and TicagrelorUta Schilling, Jasper Dingemanse, Michael Dobrow, et al.
Clinical and Translational Science|April 12, 2023
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivoMarion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, et al.
International Journal of Molecular Sciences|December 7, 2017
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy SubjectsPierre-Eric Juif, Daniela Baldoni, Maribel Reyes, et al.
Sleep Medicine|March 20, 2022
Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apneaMarie-Laure Boof, Mike Ufer, Ingo Fietze, et al.
Pageof 24

Showing results (191-200 of 238) with videos related to

Sort By:
Pageof 24
Antimicrobial Agents and Chemotherapy|November 26, 2014
First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activityShirin Bruderer, Noémie Hurst, Ruben de Kanter, et al.
Journal of Clinical Pharmacology|February 29, 2008
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsRebecca E Wrishko, Jasper Dingemanse, Albert Yu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|September 22, 2009
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentanOliver Kummer, Manuel Haschke, Felix Hammann, et al.
Drug Design, Development and Therapy|January 2, 2015
A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonistMatthias Hoch, Borje Darpo, Tatiana Remenova, et al.
Clinical Pharmacology and Therapeutics|April 15, 2022
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive SimulatorClemens Muehlan, Sander Brooks, Cedric Vaillant, et al.
Journal of Psychopharmacology (Oxford, England)|June 15, 2012
Orexin receptor antagonism: an ascending multiple-dose study with almorexantPetra Hoever, Sanne L de Haas, Georg Dorffner, et al.
Thrombosis and Haemostasis|January 7, 2021
Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and TicagrelorUta Schilling, Jasper Dingemanse, Michael Dobrow, et al.
Clinical and Translational Science|April 12, 2023
Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivoMarion Anliker-Ort, Jasper Dingemanse, Stephane Delahaye, et al.
International Journal of Molecular Sciences|December 7, 2017
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy SubjectsPierre-Eric Juif, Daniela Baldoni, Maribel Reyes, et al.
Sleep Medicine|March 20, 2022
Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apneaMarie-Laure Boof, Mike Ufer, Ingo Fietze, et al.
Pageof 24